Praveen G Ranganath1, Albree Tower-Rader2. 1. Department of Radiology, Massachusetts General Hospital, Boston, MA, USA. 2. Division of Cardiology, Department of Medicine, Harvard Medical School, Massachusetts General Hospital, 55 Fruit St, Yawkey 5B, Boston, MA, 02114, USA. atower-rader@mgh.harvard.edu.
Abstract
PURPOSE OF REVIEW: Diagnosis of infiltrative cardiomyopathies can be challenging despite differences in clinical manifestations due to overlapping cardiac manifestations. We review the salient findings by cardiac magnetic resonance imaging that aids in diagnosis, as well the potential implications for prognosis and treatment. RECENT FINDINGS: Cardiac magnetic resonance imaging has added substantially to our understanding of various infiltrative cardiomyopathies, and the addition of late gadolinium enhancement imaging and parametric mapping has yielded additional insights regarding potential diagnoses, prognosis, and therapy. Cardiac magnetic resonance imaging should be employed in the setting of suspected hypertrophic or infiltrative cardiomyopathies to aid in diagnosis. In the setting of cardiac amyloidosis and Fabry disease, there is data to suggest that cardiac magnetic resonance imaging is useful for risk stratification as well as for monitoring response to therapy.
PURPOSE OF REVIEW: Diagnosis of infiltrative cardiomyopathies can be challenging despite differences in clinical manifestations due to overlapping cardiac manifestations. We review the salient findings by cardiac magnetic resonance imaging that aids in diagnosis, as well the potential implications for prognosis and treatment. RECENT FINDINGS: Cardiac magnetic resonance imaging has added substantially to our understanding of various infiltrative cardiomyopathies, and the addition of late gadolinium enhancement imaging and parametric mapping has yielded additional insights regarding potential diagnoses, prognosis, and therapy. Cardiac magnetic resonance imaging should be employed in the setting of suspected hypertrophic or infiltrative cardiomyopathies to aid in diagnosis. In the setting of cardiac amyloidosis and Fabry disease, there is data to suggest that cardiac magnetic resonance imaging is useful for risk stratification as well as for monitoring response to therapy.
Authors: Aleš Linhart; Dominique P Germain; Iacopo Olivotto; Mohammed M Akhtar; Aris Anastasakis; Derralynn Hughes; Mehdi Namdar; Maurizio Pieroni; Albert Hagège; Franco Cecchi; Juan R Gimeno; Giuseppe Limongelli; Perry Elliott Journal: Eur J Heart Fail Date: 2020-08-14 Impact factor: 15.534
Authors: Ryan S D'souza; Cecilia Levandowski; Dobromir Slavov; Sharon L Graw; Larry A Allen; Eric Adler; Luisa Mestroni; Matthew R G Taylor Journal: Circ Heart Fail Date: 2014-09 Impact factor: 8.790
Authors: Barry J Maron; William C Roberts; Michael Arad; Tammy S Haas; Paolo Spirito; Gregory B Wright; Adrian K Almquist; Jeanne M Baffa; J Philip Saul; Carolyn Y Ho; Jonathan Seidman; Christine E Seidman Journal: JAMA Date: 2009-03-25 Impact factor: 56.272